arrow
J

Jonathan T. Lei

baylor college of medicine
H指数:26
被引数:5,871

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasis (vol 655, 218636, 2026)

NF1在雌激素受体阳性乳腺癌中的缺失诱导破骨细胞形成和免疫抑制以促进骨转移(卷655,218636,2026)

2026-09-010
PRE
Co-occurrence of transcriptionally distinct persister cell states underpins neoadjuvant therapy resistance in triple‑negative breast cancer

转录异质性持久细胞状态的共发生是三阴性乳腺癌新辅助治疗耐药的基础

2026-04-090
OA
NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors

NF1-depleted ER+乳腺癌对CDK4/6抑制剂的敏感性存在差异。

2025-08-270
PRE
Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures

不同种族和暴露因素下肺腺癌的整合分析

2025-07-310
OAAI
Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer

蛋白质组学表征揭示了与肌肉浸润性膀胱癌化疗耐药相关的生物标志物

2025-07-310
OAAI
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers

CALGB 40601 (Alliance) HER2+乳腺癌新辅助试验的蛋白质组学分析揭示了耐药生物标志物

2025-06-050
OA
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into ARness ''
2024-06-011
OAAI
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
2024-05-232
OAAI
Proteogenomic approaches for the identification of NF1/neurofibromin-depleted estrogen receptor positive breast cancers for targeted treatment
2024-05-020
PRE